Why the study?
Does prospective statin administration prevent LVEF declines 2 years after doxorubicin treatment in patients with breast cancer and lymphoma?
Does prospective statin administration prevent LVEF declines 2 years after doxorubicin treatment in patients with breast cancer and lymphoma?
Prospective statin therapy does not prevent declines in left ventricular ejection fraction at 2 years in patients receiving doxorubicin for breast cancer or lymphoma.
Statin use should not yet be considered for LVEF preservation after doxorubicin; leaves open whether RCTs would demonstrate benefit.
In patients with breast cancer and lymphoma with no existing indication for statin therapy, prospective statin administration did not affect LVEF declines 2 years after doxorubicin. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT01988571.).
No takes yet. Share an insight, caveat, or question.
Hundley et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: